Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

"Blepharitis - Pipeline Review, H2 2013" now available at Fast Market Research


Print article Print article
2013-12-22 01:29:40 - Recently published research from Global Markets Direct, "Blepharitis - Pipeline Review, H2 2013", is now available at Fast Market Research

Global Markets Direct's, 'Blepharitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blepharitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blepharitis. Blepharitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot

of the global therapeutic scenario for Blepharitis.
* A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Blepharitis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Full Report Details at
- www.fastmr.com/prod/755163_blepharitis_pipeline_review_h2_2013.a ..

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Blepharitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Blepharitis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Lux Biosciences, Inc., InSite Vision Incorporated, Foamix Ltd., LABORATOIRES THEA, Kala Pharmaceuticals

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Blepharitis Overview
Therapeutics Development
An Overview of Pipeline Products for Blepharitis
Blepharitis Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Blepharitis Therapeutics - Products under Development by Companies
Companies Involved in Blepharitis Therapeutics Development
Lux Biosciences, Inc.
InSite Vision Incorporated
Foamix Ltd.
LABORATOIRES THEA
Kala Pharmaceuticals
Blepharitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(azithromycin + dexamethasone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azithromycin Xtra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LX-214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
azithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LX-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
loteprednol etabonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Blepharitis Therapeutics - Drug Profile Updates
Blepharitis Therapeutics - Dormant Products
Blepharitis - Product Development Milestones
Featured News & Press Releases
Jul 23, 2013: InSite Vision Announces Top-line Results from the DOUBle Phase 3 Clinical Study for the Treatment of Moderate-to-Severe Blepharitis
Mar 25, 2013: InSite Vision Completes DOUBle Phase III Clinical Study Of AzaSite Plus And DexaSite For Treatment Of Blepharitis
Sep 07, 2012: InSite Vision Fully Enrolls Phase III DOUBle Clinical Study Of AzaSite Plus And DexaSite For Blepharitis
May 25, 2011: InSite Vision Receives SPA From FDA For DOUBle Phase III Clinical Trial Of AzaSite Plus And DexaSite
Apr 14, 2011: InSite Vision Updates Special Protocol Assessment Submission To FDA For Phase III Trial Of AzaSite Plus And DexaSite
Oct 18, 2010: Garamycin Ophthalmic Ointment Now Available from Fera Pharmaceuticals
Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Blepharitis, H2 2013
Products under Development for Blepharitis - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=755163&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser